



NDA 022044/S-029

SUPPLEMENT APPROVAL

Merck Sharp & Dohme Corp.
Attention: Lou Ann Eader, Ph.D
Director, Worldwide Regulatory Affairs
351 N. Sumneytown Pike, P. O. Box 1000
UG 2C-50
North Wales, PA 19454-1099

Dear Dr. Eader:

Please refer to your Supplemental New Drug Application (sNDA) dated and received March 26, 2013, submitted pursuant to section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Janumet (sitagliptin and metformin HCl) tablets, 50 mg/ 500 mg and 50 mg/ 1000 mg.

We acknowledge receipt of your amendment dated August 27, 2013.

This “Prior Approval” supplemental new drug application provides for changes to multiple sections of the package insert and Medication Guide to harmonize labeling with the currently approved labeling for Janumet XR (NDA 202270/S-003, approved on February 11, 2013). This sNDA also includes annual reportable changes to the labeling.

APPROVAL & LABELING

We have completed our review of this supplemental application. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

WAIVER OF HIGHLIGHTS SECTION

Please note that we have previously granted a waiver of the requirements of 21 CFR 201.57(d)(8) regarding the length of Highlights of prescribing information.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA

automated drug registration and listing system (eLIST), as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>. Content of labeling must be identical to the enclosed labeling (text for the package insert Medication Guide), with the addition of any labeling changes in pending “Changes Being Effectuated” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.

Information on submitting SPL files using eList may be found in the guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As at <http://www.fda.gov/downloads/DrugsGuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>. The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that includes labeling changes for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Richard Whitehead, Regulatory Project Manager, at (301) 796-4945.

Sincerely,

{See appended electronic signature page}

Jean-Marc Guettier, M.D.
Director (Acting)
Division of Metabolism and Endocrinology Products
Office of Drug Evaluation II
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling
Package Insert
Medication Guide

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

JEAN-MARC P GUETTIER
09/11/2013